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Abstract: Over the last three decades, Rhenium-188 (188Re) applications in Nuclear Medicine therapies have gathered a 
lot of interest thanks to the favorable physical and chemical characteristics of this isotope. In order to optimize 188Re 
therapies, the accurate knowledge of the activity distribution within the patient body is required. To this end, the nuclear 
medicine images must yield accurate quantitative measurements. However, the decay of 188Re results in a large variety 
of emissions such as !-particles, "-particles and Bremsstrahlung, making quantitative measurements of 188Re activity a 
very difficult task. In this paper, we discuss the imaging protocols, data acquisitions, techniques used in image 
reconstruction and processing, and dose estimation methods required for accurate, image-based, personalized 
dosimetry for molecular therapies with 188Re. 
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1. INTRODUCTION 
The use of radioisotopes in cancer therapies has 
already a long history, dating from early 1900s when 
first experimental treatments of skin diseases with 
radium-226 (226Ra) were performed [1, 2]. Later, 
therapies with iodine-131 (131I), phosphorous-32 (32P), 
strontium-90 (90Sr), and yttrium-90 (90Y) have been 
developed and successfully used for treatment of 
thyroid nodules and many other malignant and benign 
conditions. However, only recently increased aware- 
ness of the need for treatment strategies which will be 
tailored for individual patient’s needs (personalized 
medicine) has led to a tremendous growth in targeted 
radionuclide therapies, with many new pharmaceuticals 
and new radioisotopes being tested in clinical trial and 
being introduced into practice [3-5]. 
The principle of targeted radionuclide therapy (TRT) 
relies on the use of a molecular carrier, labeled with a 
radioisotope, to deliver high radiation dose directly to 
the tumour. Typically, radioisotopes which are used in 
TRT decay with the emission of high energy massive 
particles (electrons or alphas), in contrast to 
electromagnetic radiation predominantly used in 
external beam radiotherapy (EBRT). These particles 
will deposit all their energy in the close proximity of the 
area with high radiopharmaceutical uptake, sparing 
areas with low uptake. For this reason, the search for 
molecules which will selectively concentrate and  
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remain in the tumor cells, thus allowing for a very 
localized dose delivery, is extremely important. Another 
critical issue is the development of methods to estimate 
delivered doses.  
Nuclear medicine (NM) imaging studies (SPECT 
and PET), performed before treatment (using 
molecules labeled with diagnostic radioisotopes, such 
as 99mTc, 111In, 68Ga or others) and/or after treatment 
(using molecules labeled with therapeutic radioiso- 
tope), provide information about radiopharmaceutical 
distribution in the patient body. This information can be 
used for the initial diagnosis of the disease and, after 
the treatment, for confirmation of the delivered therapy. 
Additionally, they can be used for the personalized, 
image-based dosimetry calculations, which are 
necessary to estimate the dose delivered to tumour(s), 
and also to healthy tissues, most importantly, to organs 
at risk.  
Since large inter-patient variability observed in 
radiotracer uptakes [6-8] may potentially lead to 
dangerous consequences, personalized dosimetry 
calculations should be performed for every patient to 
optimize his/her therapy outcomes and to minimize 
toxicity. For calculation of absorbed radiation doses 
quantitative information about the distribution of the 
radioactive material in the patient body and accurate 
information about changes in this activity distribution 
are required. These two pieces of information can be 
relatively easily obtained if the therapy radioisotope, 
besides electrons or alphas which are used to kill 
tumour cells, emits also gamma radiation which could 
be used for imaging. Several isotopes fulfill this 
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condition (for example, see Table 1 in MIRD Pamphlet 
23 [9]) and 188Re is one of them.  
In this paper, we provide a general review of the 
techniques used in personalized dosimetry calculation 
for radionuclide therapy patients. The key elements of 
the procedures, including imaging protocols, data 
acquisition, image reconstruction and processing, and 
dose estimation methods are discussed. The second 
part of the paper focuses on dosimetry for patients 
undergoing radionuclide therapies with 188Re. The 
challenges which are encountered when performing 
patient-specific dosimetry for this radioisotope are 
analyzed using examples of phantom and patient 
studies.  
2. PERSONALIZED DOSIMETRY FOR RADIO- 
NUCLIDE THERAPY 
In theory, radionuclide therapy should follow the 
same protocol as is used in EBRT. In EBRT, a 
treatment plan is created for each patient, based on 
personalized dosimetry calculations, aiming to deliver 
high radiation dose to the tumour(s), while maintaining 
radiation dose to organs at risk (OAR) below threshold 
levels to minimize adverse effects. Unfortunately, this is 
not a routine approach in radionuclide therapies; here 
typically empirically determined or fixed activities are 
being administered to all patients. Often patient weight, 
evaluation of lung shunt and ratio of tumour volume to 
normal liver are the only factors considered when 
calculating radiopharmaceutical activity to be 
administered [10-12].  
Personalized dosimetry calculations for radionuclide 
therapies are not routinely done because they are 
considered to be difficult, time consuming and 
expensive. However, there are data suggesting that 
TRT efficacy could be substantially improved by 
therapy personalization [13]. Fortunately, recent 
studies [6, 14, 15] have shown that personalized 
dosimetry calculations are possible when using a 
quantitative image reconstruction, advanced image 
analysis and dose calculation algorithms. The use of 
these techniques is also recommended by the recent 
MIRD pamphlet 23 [9] as only when using them the 
most appropriate activity to be administered to each 
individual patient can be determined.  
2.1. Internal Dosimetry Calculations 
Dosimetry calculations for internally administered 
radioisotopes are normally based on the data derived 
from scintigraphic scans (planar and/or single photon 
emission computed tomography – SPECT) or positron 
emission tomography (PET) imaging studies that can 
be combined with data from blood and/or urine 
sampling. The absorbed radiation dose delivered to an 
organ is equal to the energy deposited by all types of 
emitted radiation in this organ. It depends on the 
fraction of administered activity that accumulates and is 
subsequently retained in or cleared from this organ, as 
well as the accumulation and clearance from 
surrounding tissues. This fraction depends on the 
radiopharmaceutical kinetics and tissue properties, 
both of which are subject to patient-specific factors 
causing mentioned above inter-patient variability of the 
absorbed radiation dose per unit of administered 
activity.  
To summarize, the personalized TRT dosimetry has 
to take into account both patient-related variables and 
physics-related factors. There are two main patient-
related challenges in internal dosimetry: (1) to 
accurately determine the distribution of the injected 
radiopharmaceutical in different tissues and (2) to 
determine the pharmacokinetics of the agent in 
question in each tissue of interest. As already 
mentioned, these must be obtained from the imaging 
scans of a particular patient. Based on this information, 
Table 1: Characteristics of the 188Re Emissions (Only Emissions having Yields >1% are Listed) [51] 
  188Re T1/2 
Emax (keV) I (%) E (keV) I (%) 
 17 hours 1487.4 1.75 61-63 (X-rays) 3.8 
  1965.4 26.3 71-73 (X-rays) 1.01 
  2120.4 70.0 155.04 15.61 
    477.99 1.08 
    632.98 1.37 
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the amount of deposited energy (dose) and the 
distribution of this deposited energy (dose map) can be 
determined. Physics related factors are the types 
(particles or gammas) and the energies of radioactive 
emissions and the densities of tissues. Additionally, 
absorbed dose in tumours, OARs and other organs will 
depend on the distances between tumours and organs 
with high uptake (they will contribute to dose estimate 
in their neighborhood) and OARs and other sensitive 
organs. 
These dependencies can be expressed in a 
mathematical form. According to MIRD schema [16] the 
mean dose D rT ,TD( ) , absorbed in the target tissue, 
rT , over the dose-integration period, TD , can be 
calculated using the following equation: 
 
where:  A
!
rS ,TD( )  corresponds to the time-integrated 
activity in source organ rS  over TD , and the factor 
S rT ! rS( )  represents the dose absorbed in rT  per one 
decay of the radioisotope contained in rS . 
Dosimetry calculations can be performed using the 
“organ-level” approach, which assumes an average 
organ shape and mass and activity that is uniformly 
distributed throughout that organ. Organ-level 
calculations determine an average dose in the entire 
organ. Alternatively, “voxel-level” calculations can be 
performed allowing the user to create 3-dimensional 
(3D) maps of dose distribution within the organ or the 
entire body. 
Organ-level dosimetry calculations rely on the 
tabulated values of the S-factors [17, 18]. These S-
factors combine the physics-related information about 
the energies deposited by the radioactive emissions 
and are radioisotope-specific, with the geometrical 
information about the relative positions of organs in the 
body. Unfortunately, the tabulated S-factors have been 
created using Monte Carlo (MC) simulations of model 
human subjects which usually only very roughly 
approximate any particular patient anatomy [19, 20].  
Alternatively, for voxel-level calculations, the maps 
of activity distribution can be convolved with maps 
describing energy deposition by a given radioisotope in 
soft tissue (voxelized S-values). Although this type of 
calculation takes into account characteristics of the 
radiotracer uptake of the individual patient and his/her 
anatomy, still it assumes uniform distribution of tissue 
densities [21]. The voxelized S-values have been 
tabulated for many radiotherapy isotopes and several 
voxel sizes and are freely available [22].  
The most accurate, but also the most difficult to 
perform and time consuming dosimetry calculation will 
use the 3D images of activity distribution (from NM 
studies) and images of tissue density (from CT studies) 
to perform full MC simulation of the particle transport in 
the patient body. In this calculation each particle 
emitted by the radioisotope will be followed as it travels 
through different types of tissue and deposits its energy 
[23, 24]. 
As mentioned, the advantage of both the Voxelized 
S-Value method and the full MC simulation is that both 
these methods allow us to obtain 3-D maps of the dose 
distribution which subsequently can be segmented to 
provide dose values equivalent to those obtained from 
organ-level calculations, or can be used to generate 
dose-volume histograms, commonly used in EBRT. 
2.2. Quantification of Activity  
Conventional dosimetry calculations have almost 
always been based on planar imaging, the accuracy of 
which is limited by organ/tumour superimposition and 
background activity [25, 26]. Additionally, attenuation 
correction for planar images is only very approximate 
as, at best, it can use transmission maps measured 
using an uncollimated flood source. On the other hand, 
SPECT, a 3D imaging technique, overcomes these 
limitations and hybrid SPECT cameras combined with 
X-ray computed tomography (SPECT/CT) routinely 
compensate for attenuation. Also, in order to obtain 
truly quantitative results, corrections for other effects 
(e.g., scatter, dead-time and resolution loss) must be 
implemented [9]. Additionally, to determine 
pharmacokinetics (uptake and washout) of the 
radiotracer, a series of imaging scans must be 
performed over the time when activity changes are 
expected to occur. 
Iterative reconstruction methods, such as, maximum 
likelihood expectation maximization [27] or ordered 
subsets expectation maximization (OSEM) [28], are 
required for quantitative reconstruction because they 
allow for optimal implementation of corrections. As 
modern SPECT cameras are typically combined with 
CT scanners, attenuation correction (AC) uses patient-
specific attenuation maps obtained from the CT 
images. Additionally, accurate quantification of images 
requires scatter correction (SC) to be performed. 
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Several techniques have been proposed for scatter 
correction [29]. They range from relatively complex MC 
simulation-based approaches, through analytical 
scatter calculation to the simplest re-scaling of the 
attenuation map to the broad-beam coefficient values. 
However, this last method corrects only the total 
number of counts, not photon distribution. One of the 
simpler and also probably the most popular method is 
the triple energy window (TEW) technique [30] which 
corrects for the scattered photopeak photons (self-
scatter) and also can account for contributions from the 
scattered high energy photons and the background. 
The TEW method generates only an approximate 
estimate of scattered photon distribution, but the 
effect of this approximation is very unlikely to affect 
accuracy of patient studies.  
Finally, correction for collimator-detector response 
(CDR) is often included in the reconstruction. Although 
this correction does not change the total number of 
counts in the reconstructed image (so it does not affect 
quantitative accuracy), it improves image resolution 
thus decreases partial volume effect. The attenuation 
correction and the correction for the collimator-detector 
response (CDR) are usually incorporated directly into 
the system matrix of the reconstruction algorithm, while 
scatter correction is included only in the projector part 
of the algorithm.  
One more source of potential errors in activity 
quantification for radionuclide therapies is related to the 
detector dead-time observed when high levels of 
activity are administered. In most therapeutic studies, 
the correction for the dead-time is necessary only for 
the first imaging time-point as it is then when a very 
large flux of photons strikes the detector. The lack of 
dead-time corrections would cause under-estimation of 
activities in tumors and OARs. As a result, the 
pharmacokinetic information would not be accurately 
determined, affecting the accuracy of the dosimetry 
estimates.  
There are two methods to determine dead-time 
correction factors (DTCFs) which can be used in this 
case. In the first approach, the DTCFs are determined 
using phantom calibration experiments [31, 32]. In the 
second method, a marker (point-source) of well-known 
activity is placed within the scanner field-of-view and its 
count-rates are measured with and without the patient 
in place. The DTCF is determined from the ratio of 
counts in a small region of interest (ROI) drawn around 
the marker in the patient + marker scan (where the 
dead-time is present) and the marker alone scan [33]. 
Finally, in order to convert the counts in the 
reconstructed image into the units of activity (or activity 
concentration), a system calibration factor must be 
applied. The system calibration factor, k , can be 
determined by acquiring a tomographic acquisition of 
an extended phantom filled with activity or using a 
planar image of a point-source. In both cases the 
activity of the isotope of interest must be accurately 
known prior to the scan, and k  is obtained using the 
following formula [34, 35]: 
  k = Ct ! A  
Where: C  represents the total reconstructed counts 
in the phantom image, or in the case of planar scan, 
the image counts recorded in the photopeak window; t  
represents the acquisition time of the scan and A  
represents the activity of the isotope. During the 
acquisition, the energy window settings must be 
identical to those selected for the patient SPECT 
scans. The point-source calibration method relies on 
the assumption that scatter and attenuation within the 
point-source are minimal, so the measured counts in 
the photopeak window represent the primary photons 
only. If the isotope’s emissions include high-energy 
photons which may scatter into photopeak window (like 
is the case in 188Re), the TEW method should be 
applied to remove them from the photopeak window. 
2.3. The Imaging Protocols 
As discussed in Section 2.1, in order to evaluate the 
dose absorbed in an ROI (organ or tumour), the activity 
distribution in the tissue must be quantified, as well as 
temporal changes of this activity distribution 
(pharmacokinetics) must be determined. This last step 
requires collecting imaging data at multiple time-points 
(typically at least 2-3) and creating time-activity-curves 
(TACs) for every source region or organ, or even for 
every voxel in the image. The data necessary for TACs 
creation can be acquired using three different 
approaches: 
1. Planar scans only - the TACs are generated 
using a series of planar scans (often whole body 
- WB) where only approximate quantification of 
activity is performed. 
2. Hybrid method – the TACs are generated as in 
the planar-only method. Next, TACs are 
renormalized using a single quantitative SPECT 
image acquired during the time period covered 
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by the TAC and performed over the area which 
includes all organs and regions of interest. 
3. SPECT scans only – the TACs are generated 
using data from a series of fully quantitative 3D 
images. The use of SPECT/CT for accurate 3D 
dosimetry calculations has been recommended 
by one of the latest MIRD (Medical Internal 
Radiation Dose) publications [9]. 
In order to create TACs, all the images in the series 
that will be used for TACs creation must be co-
registered to each other and the counts in the organs 
or regions of interest (source regions) at different time 
points summed. The acquired data can then be plotted 
versus time to form TACs corresponding to all source 
regions. By fitting mono or even multi-exponential 
curves to these data and integrating the areas under 
the curve, the values of Ã rS( )  for each source region 
can be calculated. In order to determine the exact 
value of the time integrated activity, it is important to 
collect the data over a sufficiently long time interval 
(usually should be longer or much longer than the 
physical half-life of the isotope).  
Co-registration of images obtained from a sequence 
of scans may be quite challenging, as patient position 
often changes during different imaging sessions, and 
also activity distribution changes over time. For planar 
images, co-registration often uses rigid transformation 
and attempts to match organ boundaries. Then, organs 
and tumours of interest must be segmented and TACs 
are created for them, assuming pharmacokinetics to be 
the same in all voxels of each region. When a series of 
SPECT/CT scans is performed, 3D co-registration and 
3D segmentation are required. In principle, such co-
registration can be done using CT images from each 
scan, however, it is still difficult and there is no 
guarantee that SPECT and CT images (which are 
always acquired sequentially) are perfectly matched. In 
theory, co-registered 3D SPECT images can be used 
to generate TACs for every voxel. Such TACs, 
however, not only are extremely noisy, but also there is 
no guarantee that voxel matching was done correctly 
and that the registration process did not change the 
distribution of activity. Therefore, even in this case it is 
safe to assume the same pharmacokinetics in all 
voxels of each organ, similar to planar scans. 
2.4. Organ Segmentation 
Another, very challenging problem is segmentation 
of organs and tumours in NM images. The problem is 
difficult, due to poor resolution of these images (partial 
volume effect) and often non-negligible spill-in and 
spill-out between different regions. Nevertheless, such 
segmentation is necessary for generation of TACs, 
where activity in the source organs must be estimated 
in a series of images. Additionally, segmentation must 
be performed for calculation of mean doses absorbed 
in different target organs and regions. This can be done 
by segmenting quantitative images of activity 
distribution prior to performing organ-based dosimetry 
to obtain organ mean doses. Alternatively, images of 
activity distribution may be convolved with voxelized 
matrices of energy deposition to create dosimetry 
maps, which can also be segmented to calculate mean 
doses in the segmented regions. 
The most obvious segmentation method would be 
to manually draw ROI boundaries. This approach is 
relatively straightforward when segmenting planar 
images, but very tedious and difficult when a series of 
ROI must be drawn in 3D. Additionally, this 
segmentation is very subjective and may depend on 
the colour-scale used to display the image. Other 
methods which are quite popular in clinical studies, is 
to use organ boundaries visible in CT images or to 
create ROIs using a fixed threshold, and threshold 
values between 40-50% have been used [36, 37]. Due 
to the partial volume effect, CT-based segmentation 
always underestimates activity in the hot regions (and 
underestimates in cold areas), while fixed threshold 
method may produce variable results, highly dependent 
on the distribution of activity in the organ of interest and 
its immediate neighbourhood. Many more segmenta- 
tion methods with variable complexity have been 
studied [38]. In particular, adaptive thresholds have 
been proposed, where the threshold value varies 
depending on the signal-to-background (SBR) ratio 
[39]. A modification of this method proposes to use two 
thresholds: one for segmentation of activity, another for 
organ volume. The curves showing these thresholds 
dependency on the SBR must be determined using 
phantom experiments [40].  
Accurate segmentation of NM images (both SPECT 
and PET) is certainly a very important problem, which 
is currently actively investigated by many researchers 
[41].  
3. DOSIMETRY FOR 188Re RADIONUCLIDE 
THERAPIES 
3.1. Current Radiotherapies with 188Re 
Currently, there are numerous clinical applications 
of 188Re radiolabeled pharmaceuticals in radionuclide 
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therapies [10]. They range from palliative treatment of 
painful bone metastases from breast [42] and prostate 
cancer [43] using 188Re-HEDP, radiation synovectomy 
treatments with188Re-colloids [44, 45], endovascular 
brachytherapy using liquid 188Re-perrhenate for 
patients with in-stent stenosis [46], radioimmuno- 
therapy applications using 188Re-labelled monoclonal 
antibodies [47, 48], to targeted therapy for lung cancers 
using 188Re-labelled somatostatin analogs [49] and 
trans-arterial radioembolization (TARE) therapy for liver 
cancers using 188Re-HDD Lipiodol [11, 50] and 188Re-
Human Serum Albumin (HSA) [12, 51].  
The largest clinical experience using 188Re-HDD 
Lipiodol as a radioembolization agent comes from a 
study sponsored by the International Atomic Energy 
Agency (IAEA) which involved centers from 8 countries 
and 185 patients [11, 50]. The IAEA study aimed to 
tailor the therapy for each patient by performing, prior 
to the treatment, a whole-body planar scan using a low 
(‘scout’) activity of 188Re-HDD Lipiodol (~200 MBq). 
From this scan, the maximum tolerated activity was 
determined by estimating the radiation absorbed dose 
to critical organs [55]. Based on previous 
pharmacokinetics studies of 131I-HDD-Lipiodol [53], the 
clearance of 188Re-HDD-Lipiodol in tissue (tumour, liver 
and lungs) was assumed to follow a mono-exponential 
function with effective half-life of 17h (i.e., equal to 
188Re physical half-life). However, this assumption was 
not verified during treatment due to the lack of post-
therapy imaging.  
The clinical experience with 188Re-HSA 
radioembolization involves two small patient studies 
done in Europe [12, 51]. Liepe et al. 2007 [51] 
investigated the feasibility of high-activity 188Re-HSA 
radioembolization. In this work, the pharmacokinetics of 
188Re-HSA were determined based on post-therapeutic 
whole-body scans acquired at 24h, 48h, 72h and 96h 
post-treatment. Despite the embolic properties of HSA, 
the authors measured the effective half-life of 188Re-
HSA in tumor to be approximately 16h, which is slightly 
less than the physical half-life of 188Re. The difference 
was explained by the biological washout of the free 
188Re that was present in the injected 
radiopharmaceutical. The uptake in the liver and liver 
metastases was measured using a single SPECT 
image acquired 48h post-therapy using a window 
centered at the 155keV photopeak of 188Re. However, 
this measurement might not be quantitatively accurate 
as SPECT image was not corrected for scatter. 
As will be shown in Sections 3.4 and 3.5, the 
accuracy of dosimetry estimates strongly depends on 
the accuracy of activity quantification and also on the 
accurate knowledge of its change over time (effective 
half-life). However, in our opinion, the effective half-life 
of 188Re in some of the radioembolization studies 
discussed above was not rigorously determined. The 
study performed by Nowicki et al 2014 [12] utilized 
quantitatively accurate 188Re SPECT images for 
patient-specific dosimetry of 188Re-HSA [34]. In this 
study, dosimetry was estimated using 188Re physical 
decay half-life as it was assumed that the microspheres 
remained in the liver permanently. However, this 
assumption was never verified.  
The determination of the effective half-life of 188Re-
Lipidol was modeled based on the study with Lipidol 
labeled with 131I, which might not have the same 
pharmacokinetics as 188Re. The investigation of 188Re-
HDD Lipiodol pharmacokinetics is especially important 
because Lipiodol does not behave like a physical 
embolic agent (as compared to glass or resin 
microspheres, or even Human-Serum Albumin).  
3.2. Decay of 188Re and its Energy Spectra 
Radioisotope 188Re decays with the half-life of 17 
hours emitting !  particles (electrons) with a maximum 
energy of 2.2MeV and also several gamma photons 
(see Table 1) [54, 55]. The strongest group of photons, 
with the energy of 155keV (15%), is well suited for 
imaging with SPECT camera. Further advantages of 
188Re are its low cost and the fact that it can be 
obtained from a generator [42, 56]. Finally, as from the 
chemical perspective, 188Re shows close resemblance 
to 99mTc, the same molecule can potentially be labelled 
with 99mTc for diagnosis and with 188Re for TRT, making 
this pair ideal for theranostic applications. If the same 
molecule can be labeled with 99mTc and with 188Re, 
imaging of 99mTc labeled compound can provide 
clinicians with diagnostic information. Additionally, 
dosimetry estimates performed for 99mTc can be used 
to predict doses which will be delivered after injection 
of the same compound labeled with188Re. 
Unfortunately, in spite of all these advantages, 
imaging of 188Re is not easy. This is because 188Re 
electromagnetic emissions, besides the 155keV 
photons which can be used for imaging, include 
bremsstrahlung (BRS) photons (generated by 
interactions of !  particles with tissue) and several 
high-energy gammas. Both, BRS and down-scattered 
high energy photons create substantial background 
underneath the 155keV photopeak. Figure 1 show an 
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example of the simulated spectrum of photons which 
will be created in water by a 188Re source. In this case 
a 1cm radius sphere filled with activity was placed in a 
20cm diameter water phantom.  
 
Figure 1: Simulated energy spectrum of the electromagnetic 
emissions accompanying 188Re decay. The spectrum 
represents photons created by a 1cm radius sphere filled with 
activity placed in a 20cm diameter water phantom. 
3.3. Optimizing 188Re Acquisitions 
The shape of the energy spectrum in Figure 1 
becomes substantially modified when photons are 
recorded by the camera with a collimator. Figure 2 
shows the change to the spectrum which was 
presented in Figure 1 caused by acquisition with the 
camera equipped with low energy (LE), medium energy 
(ME) and high energy (HE) collimators. Both, the 
detector (3/8” NaI crystal) and the collimator 
efficiencies were modeled in our simulations [57].  
Table 2 shows the relative contributions of primary, 
scattered (self-scattered and down-scattered) and BRS 
photons recorded in the 20% energy window centered 
on the 155keV photopeak. The analysis of the data in 
Figure 2 and Table 2 clearly indicates that, in spite of 
the fact that 188Re imaging is based on the low energy 
photons, the HE collimator should be used in patient 
imaging studies as it will create the best imaging 
conditions and will minimize contribution of different 
contaminants to the photopeak window. 
The same data also indicate that, although 
correction for BRS may not be necessary, scatter 
correction is essential, as even for the HE collimator, 
more than 60% of photons recorded in the photopeak 
window are not primary photons. The scatter correction 
should be applied to the data irrespectively of the 
acquisition method, planar or tomographic. Although 
the TEW scatter correction technique is only an 
approximation, it should be recommended for imaging 
of 188Re because of its ability to remove background 
from BRS and down-scatter. 
Table 2: Relative Contributions of Primary, Self-Scatter, 
Down-Scatter and Bremsstrahlung Photons to 
the 20% Energy Window Centered on 155keV 
Photopeak of 188Re. All Quantities are 
Expressed as the Percentage of the Total 
Counts in this Window 
 
Low-energy 
(LE) 
collimator 
Medium-
energy (ME) 
collimator 
High-energy 
(HE) 
collimator 
Primary 5.2 23.5 36.1 
Self-scatter 2.8 13.5 20.7 
Down-scatter 88.3 60.5 40.9 
Bremsstrahlung 3.7 2.5 2.3 
 
 
Figure 2: Simulated energy spectra of the 188Re electromagnetic emissions as would be measured by a gamma-camera 
equipped with low-energy, medium-energy and high-energy collimators. 
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3.4. Quantification of 188Re Activity in Phantoms 
As mentioned above, planar images cannot be 
properly quantified. However, when using tomographic 
acquisitions, an accurate quantification is possible 
when iterative reconstruction with a whole set of 
corrections is used. In particular, for 188Re, in spite of 
challenging conditions for data acquisition (Table 2), 
the errors in determination of the total activity in the 
phantom remained below 10% [58]. This accuracy has 
been achieved with CT-based attenuation, TEW, CDR 
and DT corrections. Figure 3 analyzes the relative 
importance of these corrections using an example of 
our phantom study. In this case, seven hot inserts 
(activity concentration was 490 kBq/mL for five spheres 
and 290 kBq/mL for two bottles) were placed in a 
thorax phantom (with cold lungs and spine inserts) 
filled with the activity concentration of 70 kBq/mL 
(source-to-background ratio = 7). The image of the true 
activity distribution was created from the CT image 
filled with true activities, as measured in an 
Atomlab100-plus dose calibrator (Biodex Medical 
Systems, USA).  
Visual analysis of images presented in Figure 3B 
and 3C clearly shows increased activity levels after 
attenuation correction is applied. Including scatter 
correction in the reconstruction (Figure 3D) improves 
contrast and removes counts from the cold regions. 
Finally, performing resolution recovery correction 
(CDR) further improves contrast and decreases partial 
volume effect. However, for small objects with sharp 
boundaries, a well-known Gibbs artefact (slight 
overestimation of activity in the center) can be 
observed. This artefact is very unlikely to appear in 
patient studies. 
Table 3 analyzes the recovery of activity in three of 
the seven hot inserts placed inside the phantom. The 
objects selected in this example are a large 196 mL 
Table 3: Recovery of 188Re Activity (MBq) in Two Spheres (S1 and S2) and a Bottle (B1) Placed Inside the Thorax 
Phantom FIlled with Radioactive Water. The Images were Acquired with HE Collimator and Reconstructed 
with no Corrections, AC Only, AC+SC and AC+SC+CDR. The Objects were Segmented using their CT Images 
Applied Corrections 
Object (Volume) True Activity (MBq) 
None AC AC+SC AC+SC+CDR 
S1 (8 mL) 3.9 0.4 1.8 1.4 2.2 
S2 (20 mL) 9.6 1.3 6.2 4.9 6.7 
B1(196 mL) 56.3 11.4 59.1 44.5 49.0 
Entire phantom 491 206.7 845.3 487.3 495.7 
 
 
Figure 3: Transaxial slices of the SPECT/CT study of a thorax phantom filled with 188Re. The phantom contains seven hot 
inserts (five are visible in this slice) and cold lungs and spine. The sequence of images shows the effects of corrections on the 
quality and quantitative accuracy of the reconstructed images. The geometry of the phantom is depicted in the CT image (A), 
then the sequence of SPECT images follows: with no correction (B), attenuation correction (C), attenuation and TEW scatter 
(D), attenuation, TEW scatter and CDR corrections (E), true activity distribution (F). The total activity in the phantom was 491 
MBq, resulting negligible camera dead-time. All images are displayed using the same maximum of the colour-scale. 
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bottle, (object B1, not shown on Figure 3) and two 
spheres: one medium size 20mL (object S2) and one 
small 8mL (object S1). As expected, when no 
corrections were applied during reconstruction (Figure 
3B), large underestimation of activity in the objects was 
observed. The use of attenuation correction without 
compensation for scatter (Figure 3C) improved the 
overall quantification accuracy in small objects and, for 
the example shown here, it yielded better activity 
recovery than when the image was corrected for 
scatter (Figure 3D). However, this apparent good 
recovery was caused by a substantial over-estimation 
of activity due to the large amount of scatter photons in 
the photopeak window that were not removed from 
the image. The application of CDR improved the 
recovery of activity for all objects within the phantom; 
its effect was most noticeable in small objects (sphere 
S1 and S2 on Figure 3). 
The limited accuracy of activity recovery in small 
objects is due to the partial volume effect which causes 
substantial spill-out. This effect is particularly 
pronounced in our data, where CT-based segmentation 
was used. On the other hand, the accuracy of 
quantitative correction can be demonstrated when total 
counts in the entire phantom are analyzed. In this case, 
the recovery of the total activity in the phantom 
compared with its true activity showed less than 2% 
difference. 
3.5. Patient Study 
Figure 4 shows a similar comparison of the 
performance of different quantitative corrections as was 
presented in Figure 3, this time applied to the patient 
study. Obviously, in this case the true activity 
distribution could not be known. The patient received 
1.3GBq of 188Re-HDD-Lipiodol for trans-arterial 
radioembolization treatment. The scan was performed 
using a SymbiaT camera (Siemens Medical, Germany) 
with HE collimator and only negligible camera dead-
time was observed. The images illustrate the effects of 
corrections on the quality and quantitative accuracy of 
the reconstructed images. The CT image shows the 
Lipiodol distribution in patient’s liver (Figure 4A), the 
following images show 188Re activity distribution in the 
corresponding slice of SPECT images. The images 
were reconstructed with no corrections (Figure 4B), 
with attenuation correction only (Figure 4C), with 
attenuation and TEW scatter corrections (Figure 4D), 
and with attenuation, TEW scatter and CDR corrections 
(Figure 4E). To better illustrate the effects of 
corrections, all the images are displayed using the 
same maximum of the colour-scale. 
The images presented in Figure 5 illustrate the 
influence of organ segmentation on dosimetry 
estimates. Transaxial slices of the liver images of two 
patients (A and B) having tumours with substantially 
 
Figure 4: Transaxial slices of the SPECT/CT study of a patient (Patient A) that received trans-arterial radioembolization 
treatment with 188Re-HDD-Lipiodol. The sequence of images shows the effects of corrections on the quality and quantitative 
accuracy of the reconstructed images. The patient anatomy showing the Lipiodol distribution in liver is depicted in the CT image 
(A), then the sequence of SPECT images follows: with no correction (B), attenuation correction only (C), attenuation and TEW 
scatter (D), attenuation, TEW scatter and CDR corrections (E). The projection data was acquired with the HE collimator. All 
images are displayed using the same maximum of the colour-scale. 
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different sizes are displayed. The volume of both 
tumours were determined from pre-treatment contrast 
CT images and were equal to 22cc and 400cc in 
Patient A and Patient B, respectively. The tumors were 
segmented by applying a threshold that recovered the 
true tumor volumes (referred in Figure 5 as ‘Boundary 
CT’) and by applying a fixed 40% threshold (‘Boundary 
40%’). For both patients, the 40% threshold 
segmentation yielded smaller (patient A) and 
substantially smaller (patient B) tumour volumes than 
those obtained from contrast-CT images (considered to 
be true volumes). This difference was particularly large 
for Patient 2, where the activity distribution in the tumor 
was nonuniform, as in this case threshold value was 
determined based on a very small area with high 
activity. 
At the next step, the effects of using these two 
different segmentation methods on the absorbed dose 
estimation were evaluated. The dose values obtained 
using tumour activities estimated with the CT-based 
method were always lower than those from the 40% 
threshold segmentation. The difference was only 50% 
for Patient A, but reached 140% level for Patient B. 
This analysis clearly indicated crucial importance of 
accurate segmentation method.  
Additionally, the effects of timing the imaging scans 
used to create TACs on the patient dose were 
estimated. The patient used in this example (Patient B) 
was scanned (whole-body planar and SPECT/CT) at 
3h, 24h and 48h after the administration of 188Re-HDD-
Lipiodol. The dosimetry calculations presented in Table 
4 were performed using TACs derived from the data 
acquired at three time-point (method A), using only two 
out of these three time-points (methods B and C) and 
using one time point with the physical half-life of 188Re 
(method D). The dose estimated using method A with 
three data-points was 20% higher than that calculated 
based on only two scans (methods B and C). The 
effective half-life of 188Re-HDD-Lipiodol in tumor 
derived from the three time-points was 12.8h, while two 
data point yielded 10.3h and 16.2h. However, the dose 
estimated using physical half-life was substantially 
higher that that obtained based on the imaging data. 
In summary, this analysis illustrates the impact of 
the method used for organ segmentation and the 
importance of the appropriate imaging protocol when 
estimating dose in radionuclide therapies. Although in 
this study we used only a few limited examples of 
phantom and patient data, our on-going analysis of the 
 
Figure 5: Transaxial slices of SPECT/CT study of two patients (Patient A and Patient B) that received trans-arterial 
radioembolization treatment with 188Re-HDD-Lipiodol. The SPECT images were reconstructed with attenuation, TEW scatter 
and CDR corrections. The boundaries of the tumors, shown on SPECT images, were determined by applying a fixed threshold 
that recovered the true tumor volumes obtained from contrast-CT images (‘Boundary CT’) and by applying a fixed 40% 
threshold. 
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larger patient populations confirms the observed 
trends.  
CONCLUSIONS 
Radionuclide therapies are gaining recognition for 
their potential to deliver targeted treatment directly to 
tumour sites using molecular nuclear medicine 
approaches. However, current treatments mostly use 
‘one-size-fits-all’ radiopharmaceutical administration, 
while the increasing body of evidence suggests that 
plans based on personalized dosimetry calculation do 
improve treatment outcomes, at the same time 
minimizing toxicity. Recent studies have shown that 
accurate image-based dosimetry is not only possible, 
but also highly recommended by the MIRD community 
[9]. However, advanced methods, based on tomogra- 
phic quantitative imaging (SPECT and PET) and taking 
into account the particularities of the decay and 
emissions of the therapeutic radioisotope in question 
must be employed. This attitude motivates the creation 
of specialized dosimetry guidelines, such as the 
recently published MIRD pamphlets for 131I [59] and 
177Lu [60].  
The material presented in this paper follows this 
philosophy. It outlines the procedures required for 
performing accurate personalized dose calculations 
based on quantitative SPECT studies and discusses 
their application for 188Re therapies. 
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